The approval of cardiac resynchronization pacemakers and defibrillators manufactured by Medtronic has been expanded to include patients with atrioventricular block and less severe heart failure, the...
WASHINGTON – Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive or submassive pulmonary embolism significantly improves right ventricular function, reduces pulmonary...
WASHINGTON – The off-label use of novel oral anticoagulants for stroke prevention in patients with valvular atrial fibrillation has climbed steeply since the drugs reached the marketplace, mirroring...
Results of TOPCAT, one of the most talked about heart failure trials in recent years, have been published. There were no obvious surprises: Spironolactone is no more beneficial than placebo for...
Fibrinolytic therapy with tenecteplase prevents hemodynamic decompensation in patients with intermediate-risk pulmonary embolism but raises the risk of major hemorrhage and stroke, so its use is...
Stress cardiac magnetic resonance is highly feasible and prognostically useful in obese patients, a population in which stress imaging methods are limited, according to a study of nearly 300 patients...
WASHINGTON – A novel pharmacologic approach to the prevention of ischemic events in patients with stable coronary heart disease failed to reduce the combined risk of cardiovascular death, acute...
The novel oral anticoagulant dabigatran has been approved for treating and reducing the risk of recurrence of deep venous thrombosis and pulmonary embolism, based on the results of four phase III...
WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us...
LAS VEGAS – Venous thromboembolism prophylaxis – a sine qua non of the Joint Commission and others – doesn’t seem to prevent deep vein thrombosis or pulmonary embolism in hospitalized medical...